This week, the U.S. Food and Drug Administration (FDA) removed 2 of 3 approved indications for the semi-synthetic macrolide antibiotic telithromycin (Ketek, manufactured by sanofi-aventis). Ketek loses its indication for (1) acute bacterial sinusitis and (2) acute bacterial exacerbations of chronic bronchitis, often abbreviated as “ABECB”. Ketek remains approved for community acquired pneumonia of mild [...]
Read the full article →
Recently newsgroup user jkellymdmph asked a question that I had brought up when Google Co-op Health first launched: How can this group health effort can resist infiltration by aggressive marketing? jkellymdmph goes on to describe a continuing medical education (CME) event he attended that was supported with an unrestricted grant from a pharmaceutical company. There [...]
Read the full article →